On April 28, 2025, Pacira BioSciences announced promising long-term results from its gene therapy, PCRX-201, for knee osteoarthritis.

The therapy demonstrated significant symptom improvement over a two-year period following a single local administration in patients with mild to severe osteoarthritis.

These findings bolster Pacira's position in the competitive landscape of osteoarthritis treatments, which currently include their existing products like EXPAREL and ZILRETTA.

In addition to PCRX-201, Pacira is also developing therapies targeting chronic pain and other serious health conditions.

To enhance shareholder value, the company recently authorized a $300 million share repurchase program.

Pacira's stock price closed at $25.72, with analysts projecting an average target price of $36.00, indicating a potential upside of nearly 40%.

The company's latest financial performance shows an adjusted EPS of $0.91 for Q4 2024, surpassing analysts' expectations of $0.84.

Pacira BioSciences has a workforce of 789 employees and focuses on non-opioid treatments for pain management and other debilitating conditions.